Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyAetna Nebulizers Coverage & Prior Auth Policy | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0065

    Nebulizers

    Customize your policy alerts

    Sign up for Aetna Policy 0065 alerts

    Get alerted when Policy 0065 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, limits, and coding for small-, large-, and ultrasonic-volume nebulizers, related compressors, accessories, and inhalation drug administration for Aetna members.

    Policy Summary
    PayerAetna
    PolicyNebulizers
    Policy CodePolicy 0065
    Change TypeNo material change
    Effective DateDec 4, 1995
    Last ReviewMar 17, 2023
    Next Review DateJan 11, 2024
    Key ActionPrior authorization required per policy for covered nebulizer equipment, accessories, and specified nebulized drug products when selection criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10+listed indications for small volume nebulizer
    15 itemsaccessory replacement frequency entries
    70+procedure/drug codes enumerated
    8interventions experimental/investigational
    115+bibliographic references

    Coverage Criteria for Nebulizers and Related Therapies

    inv-01: Small Volume Nebulizer - Medical Necessity Indications

    Aetna considers the use of a small volume nebulizer and related compressor DME medically necessary when ANY of the following are met:

    Small volume nebulizer indications: 1. To administer antibiotics (gentamicin, amikacin, or tobramycin) to members with cystic fibrosis (CF) or bronchiectasis; OR 2. To administer beta-adrenergics (e.g., albuterol), anticholinergics (e.g., ipratropium), corticosteroids (e.g., budesonide), and cromolyn for management of chronic obstructive pulmonary diseases (COPD) including chronic bronchitis, emphysema, or asthma (physician must have considered MDI with/without spacer and found insufficient); OR 3. To administer dornase alfa (Pulmozyme) to members with CF or primary ciliary dyskinesia (use of Pulmozyme for non-CF indications is experimental/investigational); OR 4. To administer epinephrine for treatment of croup; OR 5. To administer formoterol (Perforomist) or arformoterol (Brovana) for maintenance treatment of COPD when applicable pharmacy medical necessity criteria are met; OR 6. To administer treprostinil (Tyvaso) or iloprost (Ventavis) for pulmonary arterial hypertension using the specified delivery systems; OR 7. To administer mucolytics (other than dornase alfa) for persistent thick or tenacious secretions; OR 8. To administer pentamidine for members with HIV, pneumocystosis, or complications of organ transplant; OR 9. To administer colistin for multidrug-resistant Pseudomonas aeruginosa pneumonia when IV therapy has failed; OR 10. To administer aztreonam inhalation solution (Cayston) for persons with CF with Pseudomonas aeruginosa (must be administered with the Altera Nebulizer System).

    Prescriber must document consideration of MDI when relevant; Altera required for Cayston; Pulmozyme limited to CF/primary ciliary dyskinesia.

    Policy Summary
    PayerAetna
    PolicyNebulizers
    Policy CodePolicy 0065
    Change TypeNo material change
    Effective DateDec 4, 1995
    Last ReviewMar 17, 2023
    Next Review DateJan 11, 2024
    Key ActionPrior authorization required per policy for covered nebulizer equipment, accessories, and specified nebulized drug products when selection criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Nebulizers and Related TherapiesBilling Codes and Accessory Replacement FrequenciesProvider Requirements, Prior Authorization, and DocumentationClinical Background and Evidence SummaryDefinitions and Device TerminologyPolicy Revision History

    inv-02: Large Volume Nebulizer - Medical Necessity Indications

    A large volume nebulizer and related compressor and water/saline DME are medically necessary when ANY of the following are met:

    Large volume nebulizer indications: 1. Administration of pentamidine for members with HIV, pneumocystosis, or complications of organ transplants; OR 2. Bronchiectasis; OR 3. Cystic fibrosis; OR 4. Presence of a tracheobronchial stent; OR 5. Tracheostomy.

    Large volume nebulizer is considered experimental/investigational for all other indications.

    inv-03: Ultrasonic Nebulizers - Medical Necessity Conditions

    Ultrasonic nebulizers are medically necessary only when ALL of the following criteria are met:

    Ultrasonic nebulizer criteria: 1. The member meets the criteria for a standard (small volume) nebulizer; AND 2. The primary care physician and a specialist indicate the member has been compliant with other nebulizer and medication therapy; AND 3. Use of a standard nebulizer has failed to control the member's disease and prevent hospital or emergency room utilization.

    Ultrasonic nebulizers are experimental/investigational for indications other than those listed.

    inv-04: Replacements - Medical Necessity

    For members with DME benefits, replacement of nebulizers is medically necessary when BOTH criteria are met:

    Replacement criteria: 1. The primary care physician and/or specialist confirm that the member has been compliant with the nebulizer and anticipate continued need to prevent hospital admission or emergency room visits; AND 2. The warranty has expired.

    Usual maximum replacement frequencies for accessories are specified in the policy appendix and requests beyond those intervals require justification.

    inv-05: General coverage principles and evidence-based device/drug use

    Coverage depends on documented medical necessity and applicable selection criteria; specific medication and device approvals are based on indication and evidence.

    Documentation and claims: Plan of care must specify the patient's condition justifying medical necessity for each item; drug orders must specify drug name, concentration or mg amount, and volume; a narrative diagnosis and/or ICD code must be present on each order and claim.

    Supports coverage determinations and possible denials if missing

    Nebulized antibiotic therapy in CF: Evidence supports aerosolized tobramycin (TOBI/TNS) for maintenance therapy in CF patients chronically infected with Pseudomonas aeruginosa; Cayston (aztreonam) is FDA-approved to improve respiratory symptoms in CF patients with P. aeruginosa (age ≥7 years; 75 mg TID; 28 days on/28 days off).FEV1 25%–75% for TOBI per FDA labeling

    Specific selection criteria and device compatibility (Altera for Cayston) must be followed and documented.

    inv-06: Bronchiolitis management

    Guidance on bronchiolitis and viral wheeze

    Bronchiolitis supportive care first: Supportive care (oxygenation, hydration, pulse oximetry) is the cornerstone of therapy for bronchiolitis; inhaled bronchodilators and corticosteroids lack consistent efficacy and should not be used routinely.

    References include systematic reviews and randomized trials noting lack of consistent benefit.

    inv-07: Croup — nebulized epinephrine

    Croup treatment with nebulized epinephrine

    Nebulized epinephrine for moderate-severe croup: Nebulized epinephrine produces a clinically and statistically significant transient reduction in croup symptoms at 30 minutes post-treatment and may shorten hospital stay; racemic and L-epinephrine show no consistent superiority and either form is acceptable per availability.

    Treatments may be repeated every 15–20 minutes if clinically warranted; repeated frequent dosing suggests need for higher level of care.

    inv-08: Hypertonic saline (3%)

    Hypertonic saline (3%) for bronchiolitis in hospitalized infants

    HTS use and outcomes: Use of 3% hypertonic saline in hospitalized infants showed no difference in mean length of stay overall in propensity-matched analyses, though daily HTS was associated with decreased odds of staying >4 days in one analysis; substantial inter-hospital variation exists.

    Further research is needed to standardize use and define which infants benefit most.

    inv-09: Nebulized LABAs (Brovana, Perforomist)

    LABA nebulized agents for COPD

    LABA indication and limits: Arformoterol (Brovana) and formoterol (Perforomist) are indicated for twice-daily maintenance treatment of bronchoconstriction in COPD; they are not indicated for acutely deteriorating COPD, are not appropriate as asthma monotherapy (require concurrent inhaled corticosteroid for asthma), and should not be used concurrently with other LABAs.

    LABAs carry boxed warnings regarding asthma-related risks; follow labeled dosing and REMS/education requirements as applicable.

    inv-10: Inhaled prostanoids (Tyvaso, Ventavis)

    Inhaled prostacyclin analogues for PAH

    Tyvaso and Ventavis indications and dosing: Tyvaso (treprostinil) and Ventavis (iloprost) are indicated for WHO Group 1 pulmonary arterial hypertension to improve exercise tolerance and symptoms; Tyvaso is dosed in four treatment sessions per day via the specified Optineb/Tyvaso system with titration by breaths per session; Ventavis is inhaled multiple times per day (6–9 times/day) with a maximum daily dose evaluated of 45 mcg and must be used with designated delivery devices; monitor for bronchospasm and hypotension.

    Avoid concurrent use with other prostanoids and use only with device-specific delivery systems.

    inv-11: Inhaled antibiotics — indications and monitoring

    Inhaled antibiotics in cystic fibrosis and bronchiectasis

    CF with Pseudomonas indication: Aztreonam (Cayston) and tobramycin inhalation are indicated to improve respiratory symptoms in CF patients with Pseudomonas aeruginosa (Cayston for patients ≥7 years administered 75 mg TID; tobramycin solution 300 mg q12h or Podhaler 112 mg q12h), with device-specific administration and 28-day on/28-day off cycles commonly used for tobramycin and Cayston.

    Use only when Pseudomonas infection is present to reduce resistance risk; Cayston requires the Altera Nebulizer System; consider FDA age/FEV1 limitations.

    Monitoring for inhaled aminoglycosides: Patients receiving inhaled tobramycin should have baseline and ongoing monitoring when indicated: renal function (BUN, creatinine, urinalysis) and audiology (audiogram 500–8000 Hz) if concomitant nephrotoxic/ototoxic agents are used or there is preexisting dysfunction; initial administration should be observed to monitor for bronchospasm.

    Evaluate long-term efficacy within 6–12 months of initiating therapy.

    inv-12: Nebulized therapies for refractory dyspnea

    Nebulized therapies for refractory dyspnea

    Nebulized medications for dyspnea: Evidence for nebulized morphine is mixed; potential benefit has been suggested for nebulized furosemide, hydromorphone, and fentanyl in limited studies, but overall evidence is insufficient — use on a case-by-case basis when potential benefits outweigh harms.

    More and larger, longer-term studies are needed; consider disease characteristics and delivery device when assessing utility.

    inv-13: Tobramycin inhalation therapy (CF)

    Covered when ALL of the following are met

    Tobramycin dosing and indication: 1. Patient receives tobramycin inhalation solution 300 mg every 12 hours or tobramycin inhalation powder (Podhaler) 112 mg every 12 hours administered in cycles of 28 days on followed by 28 days off; AND 2. Treatment is intended for eradication or suppression of Pseudomonas aeruginosa in cystic fibrosis or for a proven/strongly suspected bacterial infection or a prophylactic indication.

    Dose is the same regardless of age or weight; solution administered via jet (breath-enhanced) nebulizer producing 1–5 micron particles; Podhaler capsules used with provided device.

    Monitoring and safety: Initial dose given in presence of a trained health professional to observe for bronchospasm and instruct on delivery; monitor renal function and audiology when concomitant nephrotoxic/ototoxic agents are used or preexisting dysfunction is present; instruct patient/caregiver to stop medication and contact physician for adverse reactions.

    Routine serum tobramycin monitoring generally unnecessary with recommended dosing and normal renal function; evaluate efficacy within 6–12 months.

    Contraindications/precautions: Avoid mixing tobramycin with other nebulized medications; and avoid prescribing tobramycin when there is no proven or strongly suspected bacterial infection or prophylactic indication due to risk of resistance.

    inv-14: Accessory replacement frequency (Usual Maximums)

    Accessory replacement frequency — usual maximum medically necessary frequencies

    Accessory frequency list: Coverage of accessory replacements is guided by the usual maximum replacement intervals (examples): face tent — 1/month; administration set with small volume nonfiltered pneumatic nebulizer, disposable — 2/month; dome and mouthpiece for small volume ultrasonic nebulizer — 2/year; immersion external heater for nebulizer — 1/3 years; durable bottle-type nebulizer — 1/3 years. Requests beyond these intervals require documentation supporting medical necessity.

    The policy appendix contains the complete list of items and exact replacement frequencies.

    Aetna designates the use of nebulizers and related equipment as experimental/investigational (not covered) when they are used for indications that are not specifically listed as medically necessary in this policy. Examples of interventions explicitly identified as experimental or investigational include nebulized corticosteroids for nasal polyps or viral wheeze, nebulized lidocaine (for NGT insertion or chronic cough), nebulized magnesium for pediatric asthma, nebulized sodium nitrite, nebulized heparin for inhalation injury, and the Amnio Breathe Nebulizer. Claims for equipment or drugs used outside the policy’s listed indications are at risk for denial unless documentation demonstrates a listed medically necessary indication.

    Example ICD-10 diagnoses referenced in the policy (not exhaustive) include codes for cystic fibrosis (e.g., E84.0–E84.9), chronic lower respiratory diseases (e.g., J40–J47.9), primary pulmonary hypertension (I27.0), bronchiectasis (J47.0–J47.9), tracheostomy status (Z93.0), and acute viral respiratory infections or viral wheeze which are listed as not covered when the indication is limited to nebulized corticosteroid therapy (J00–J06.9).

    Brovana (arformoterol) and Perforomist (formoterol fumarate) are labeled for maintenance treatment of bronchoconstriction in COPD with recommended twice-daily dosing and are not indicated for acute deteriorations. Importantly, these LABA nebulized agents are not appropriate as monotherapy for asthma and should not be used in asthma patients in the absence of concurrent inhaled corticosteroid therapy. The policy also notes FDA REMS requirements and that mixing these agents with other nebulized drugs has not been established as safe or effective, so compatibility must be verified before combined use.

    Cayston (aztreonam inhalation solution) is indicated to improve respiratory symptoms in CF patients with Pseudomonas aeruginosa and is approved for patients 7 years and older, dosed as 75 mg three times daily in 28-day on/28-day off cycles. The policy states that safety and effectiveness have not been established in pediatric patients younger than 7 years and in patients with baseline FEV1 <25% or >75% predicted, and therefore those populations are outside the established labeled indication.

    Tobramycin inhalation solution and powder should not be mixed with other medications in the nebulizer. The policy explicitly states that mixing tobramycin with other nebulized drugs is contraindicated because compatibility, efficacy, and safety have not been established and co-nebulization may increase risk or reduce effectiveness.

    The Amnio Breathe Nebulizer (liquid allograft) is described in web-sourced promotional material but is not supported by UpToDate reviews cited in the policy. Aetna identifies Amnio Breathe as an unestablished topical application and includes it among interventions lacking sufficient evidence; use for respiratory conditions is not supported by the clinical references used in this policy.

    This Clinical Policy Bulletin provides a summary of indications, limits, and documentation expectations for nebulizer equipment, accessories, and select inhalation drugs. It is a tool to assist in administering plan benefits but is a partial, general description and does not constitute a contract or guarantee of coverage. Coverage determinations remain subject to plan benefit terms, individual medical necessity review, and the presence of required clinical documentation.

    Device-specific delivery characteristics affect clinical use: the policy recognizes the Pari‑LC/Pari‑C Plus breath‑enhanced jet nebulizer as useful for delivering adequate concentrations of tobramycin and cites Cystic Fibrosis Foundation guidance favoring the Pari‑C Plus for tobramycin. By contrast, the policy notes that ultrasonic nebulizers are inefficient for delivering budesonide and are not recommended for that indication; therefore device selection should match the drug’s labeled delivery system and evidence for efficient particle generation.

    Systematic reviews and trials do not provide convincing evidence to support routine use of nebulized morphine, other nebulized opioids, or nebulized corticosteroids to relieve dyspnea or chronic cough. The policy cites structured reviews and Cochrane-type analyses concluding that the evidence for nebulized opioids is inadequate or of very low quality and that systemic (oral or parenteral) opioids—not nebulized—have the stronger evidence for palliation when opioids are appropriate.

    For bronchiolitis, the policy emphasizes that supportive care (oxygenation, hydration, pulse oximetry) is the cornerstone of treatment. Multiple reviews and trials have failed to show consistent benefit for routine use of inhaled bronchodilators or corticosteroids in bronchiolitis, and these therapies should not be used routinely for most infants; use should follow evidence-based guidance and individual clinical judgement.

    The policy cautions that prescribing inhaled antibiotics (such as tobramycin or aztreonam) without documented or strongly suspected bacterial infection or an accepted prophylactic indication is discouraged. Unwarranted use increases the risk of drug‑resistant organisms and is unlikely to provide clinical benefit; such uses may be considered not medically necessary or subject to denial.

    Specifically, tobramycin prescribed in the absence of a proven or strongly suspected bacterial infection, or without an accepted prophylactic indication, is unlikely to be approved. The policy notes resistance risk and states that such prescribing is unlikely to provide benefit and may be denied.

    Randomized trials and meta-analyses cited in the policy show that nebulized magnesium sulfate has not demonstrated a significant benefit for pediatric acute asthma, whereas IV magnesium demonstrated benefit in some analyses. On this basis, nebulized magnesium is not supported as effective and is not routinely recommended for pediatric acute asthma.

    Systematic reviews and randomized trials summarized in the policy conclude that current evidence does not provide convincing support for nebulized opioids to relieve breathlessness or cough. The evidence base is heterogeneous and generally low or very low quality; therefore nebulized opioids are not routinely recommended and should be considered only when potential benefits outweigh risks and when alternative, evidence-based options are unsuitable.

    UpToDate resources referenced in the policy do not mention the Amnio Breathe Nebulizer or liquid allograft as a treatment for COPD or related respiratory conditions. The policy therefore identifies Amnio Breathe as an intervention lacking supportive evidence in major clinical reviews and not established as a therapeutic option for respiratory disease.

    Billing Codes and Accessory Replacement Frequencies

    Covered CPT/HCPCS/J codes (selected highlights)mixedCovered
    94640Pressurized or nonpressurized inhalation treatment for acute airway obstruction and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or IPPB device
    94642Aerosol inhalation of pentamidine for pneumocystis carinii pneumonia treatment or prophylaxis
    94664Demonstration and/or evaluation of patient utilization of aerosol generator, nebulizer, MDI or IPPB device
    99601Home infusion/specialty drug administration, per visit (up to 2 hours)
    99602Each additional hour home infusion/specialty drug administration
    A7003Administration set, with small volume nonfiltered pneumatic nebulizer, disposable
    A7004Small volume nonfiltered pneumatic nebulizer, disposable
    A7005Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable
    A7006Administration set, with small volume filtered pneumatic nebulizer
    E0565Compressor, air power source for equipment which is not self-contained or cylinder driven
    1–10 of 24
    1/3
    HCPCS codes not coveredHCPCSNot Covered
    A7007Large volume nebulizer, disposable, unfilled, used with aerosol compressor
    A7008Large volume nebulizer, disposable, prefilled, used with aerosol compressor
    ICD-10 codes not covered for Pulmozyme/nebulized lidocaine indicationsICD-10Not Covered
    E75.242Niemann-Pick disease type C
    R05.1 - R05.9Cough
    ICD-10 codes covered if selection criteria are metICD-10
    E84.0 - E84.9Cystic fibrosis
    B20Human immunodeficiency virus [HIV] disease
    B59Pneumocystosis
    J40 - J47.9Chronic lower respiratory diseases
    J05.0Acute obstructive laryngitis [croup]
    I27.0Primary pulmonary hypertension
    ICD-10 codes covered if selection criteria are metICD-10Covered
    B20Human immunodeficiency virus [HIV] disease
    B59Pneumocystosis
    E84.0 - E84.9Cystic fibrosis
    J47.0 - J47.9Bronchiectasis
    J95.00 - J95.09Tracheostomy complications
    Q33.4Congenital bronchiectasis
    R09.3Abnormal sputum
    T86.00 - T86.99Complications of transplanted organs and tissue
    Z43.0Encounter for attention to tracheostomy
    Z93.0Tracheostomy status
    HCPCS/J-codes covered if selection criteria are metHCPCSCovered
    A7014Filter, non-disposable, used with aerosol compressor or ultrasonic generator
    A7016Dome and mouthpiece, used with small volume ultrasonic nebulizer
    E0574Ultrasonic/electronic aerosol generator with small volume nebulizer
    J7682Tobramycin, inhalation solution, FDA-approved final product, noncompounded, unit dose form, administered through DME, per 300 mg
    J7685Tobramycin, inhalation solution, compounded product, administered through DME, unit dose form, per 300 mg
    Other HCPCS/J-codes related to nebulizer DME and drugsHCPCS
    J2001Injection, lidocaine HCL for intravenous infusion, 10 mg
    A7007Large volume nebulizer, disposable, unfilled, used with aerosol compressor
    A7008Large volume nebulizer, disposable, prefilled, used with aerosol compressor
    A4619Face tent
    A7003Administration set, with small volume nonfiltered pneumatic nebulizer, disposable
    A7004Small volume nonfiltered pneumatic nebulizer, disposable
    A7005Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable
    A7006Administration set, with small volume filtered pneumatic nebulizer
    A7010Corrugated tubing, disposable, used with large volume nebulizer, 100 ft.
    A7012Water collection device, used with large volume nebulizer
    1–10 of 22
    1/3
    CPT and other procedure codes related to nebulizer therapyCPT
    94640Pressurized or nonpressurized inhalation treatment for acute airway obstruction and/or sputum induction
    94642Aerosol inhalation of pentamidine for PCP treatment or prophylaxis
    94664Demonstration and/or evaluation of patient utilization of aerosol generator, nebulizer, MDI or IPPB device
    99601Home infusion/specialty drug administration, per visit (up to 2 hours)
    99602Each additional hour (list separately)
    HCPCS codes for nebulized corticosteroids/solutionsHCPCS
    J7622Beclomethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg
    J7626Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg
    J7627Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
    J7633Budesonide, inhalation solution, FDA-approved final product, noncompounded, concentrated form, per 0.25 mg
    J7634Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg
    J7641Flunisolide, inhalation solution, compounded product, administered through DME, unit dose, per mg
    J7683Triamcinolone, inhalation solution, compounded product, administered through DME, concentrated form, per mg
    J7684Triamcinolone, inhalation solution, compounded product, administered through DME, unit dose form, per mg
    ICD-10 codes not covered for indications listed in the policyICD-10Not Covered
    D56.1Beta thalassemia
    I27.0Primary pulmonary hypertension
    I27.20 - I27.29Other secondary pulmonary hypertension
    ICD-10 codes not covered for indications listed in the policy (nebulized corticosteroids)ICD-10Not Covered
    J00 - J06.9Acute respiratory infections [viral wheezing]
    J33.0 - J33.9Nasal polyp
    Accessory replacement frequencies — examples and typical intervals
    Administration set (small volume, non-filtered, disposable)Usual maximum replacement: 2 per month.
    Dome and mouthpiece (small volume ultrasonic nebulizer)Usual maximum replacement: 2 per year.
    Immersion external heater for nebulizerUsual maximum replacement: 1 per 3 years.
    Face tentUsual maximum replacement: 1 per month.
    Tobramycin (TOBI) FDA indication FEV1 — FEV1 25% to 75% predicted
    FDA-indicated FEV1 range for TOBI/TNS25% to 75% of predicted FEV1.
    Indication contextMaintenance therapy in CF patients colonized with Pseudomonas aeruginosa and able to comply with regimen.
    Not approved for acute pulmonary exacerbationsTOBI was not approved for therapy of acute pulmonary exacerbations or for use in non-CF patients.
    Cayston age — 7 years and older; 75 mg three times daily for 28 days on/28 days off
    Minimum ageCayston (aztreonam inhalation) is approved for patients 7 years of age and older.
    Dosing regimen75 mg inhaled three times daily (TID) administered as 1 single-use vial reconstituted with 1 mL diluent.
    Treatment cycle28 days on therapy followed by 28 days off.
    FEV1 percentage thresholds — severity categories by percent predicted
    Normal> 90% of predicted FEV1.
    Mild impairment70%–89% of predicted FEV1.
    Moderate impairment40%–69% of predicted FEV1.
    Severe impairment< 40% of predicted FEV1.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Equipment coverage requires documented medical necessity

    Durable nebulizer equipment and certain related HCPCS/CPT codes are covered only when the member meets the policy’s selection and medical necessity criteria; the plan of care must document the condition justifying medical necessity and the drug order must specify drug name, concentration or mg amount, and volume. Claims must include a narrative diagnosis and/or ICD code on each order and claim, and the patient's medical record must support medical necessity for all equipment, accessories, and drugs ordered.

    • Equipment coverage contingent on meeting the listed indications and selection criteria in the policy.
    • Plan of care and drug orders must include specific drug details (name, concentration/mg, and volume) and an accompanying narrative diagnosis/ICD code.
    • Medical record must document support for medical necessity of equipment, accessories, and drugs.
    Prior Authorization

    Prior authorization required for nebulizer DME and listed nebulized drugs

    Prior authorization is required per the policy for covered nebulizer equipment, accessories, and specified nebulized drug products when selection criteria are met; submit the applicable HCPCS/J-codes listed in the policy with the request.

    • Include the HCPCS/J-codes indicated by the policy when requesting authorization.
    • Requests for devices or drugs that meet selection criteria should be routed through prior authorization per plan rules.
    Documentation Required

    Verify indication and device compatibility with product labeling

    Verify the indication and that the prescribed device/delivery system matches product labeling (e.g., Cayston must be administered with the Altera Nebulizer System; Brovana/Perforomist are for COPD maintenance and have specific dosing constraints).

    • Confirm Cayston (aztreonam) will be used with the Altera Nebulizer System per FDA labeling.
    • Confirm Brovana (arformoterol) and Perforomist (formoterol) are prescribed only for indicated COPD maintenance use and following pharmacy criteria.
    • For prostanoids (Tyvaso, Ventavis), verify device-specific delivery and dosing schedule and monitor for known adverse effects (e.g., bronchospasm).
    Documentation Required

    Follow tobramycin dosing cycles and document supervised initiation and monitoring

    When prescribing inhaled tobramycin, follow labeled dosing and monitoring: solution 300 mg inhaled every 12 hours (28 days on/28 days off) or Podhaler 4 × 28 mg (112 mg) every 12 hours (28 days on/28 days off); initial dose should be given under observation and baseline/ongoing renal and audiology monitoring documented when indicated.

    • Tobramycin inhalation solution: 300 mg by inhalation over ~15 minutes q12h; administer via jet (breath-enhanced) nebulizer.
    • Tobramycin inhalation powder (Podhaler): four 28 mg capsules (112 mg) inhaled q12h; use Podhaler device and store capsules in blister until use.
    • Initial administration must occur in presence of trained health professional to monitor for bronchospasm; monitor BUN/creatinine and urinalysis and perform audiogram (500–8000 Hz) if concomitant nephrotoxic/ototoxic agents, preexisting dysfunction, or symptoms.
    Prior Authorization

    Prior authorization and justification required for out-of-cycle replacements

    Requests for replacements of durable nebulizers or accessories beyond the policy’s listed 'usual maximum' replacement intervals may require prior authorization and must be justified with documentation supporting medical necessity.

    • Provide physician confirmation of continued need, member compliance, and warranty status when requesting replacement.
    • If the requested replacement frequency exceeds the policy’s usual maximum (e.g., face tent 1/month; small volume disposable nebulizer 2/month; durable bottle-type 1/3 years), include clinical justification.
    Prior Authorization

    No additional PA code list provided in policy text — use HCPCS/J-codes and selection criteria

    The policy text in these chunks does not enumerate explicit prior authorization codes or a separate prior authorization process detail; use the HCPCS/J-codes and selection criteria listed in the policy when submitting requests and follow plan-specific PA procedures.

    • No discrete PA form or code list is specified in these sections — include policy-based documentation and applicable HCPCS/J-codes with authorization requests.
    • Follow the payer’s standard prior authorization submission pathways.
    Step Therapy

    Document trial/consideration of MDI ± spacer before nebulizer when required

    When criterion B (COPD/asthma drug delivery) applies, the physician must document that an MDI with or without a spacer was considered and found insufficient before a nebulizer is deemed necessary.

    • Document attempted/considered MDI therapy (with or without spacer) and the clinical rationale why MDI was inadequate.
    • Include this documentation in the plan of care and authorization request when applicable.
    Note

    Prefer evidence-based inhaled antibiotics for CF with Pseudomonas

    Evidence supports aerosolized tobramycin (TOBI/TNS) for maintenance therapy in CF patients chronically infected with Pseudomonas aeruginosa — consider tobramycin (or Cayston) per labeled indications and documented infection status.

    • Ensure documentation of chronic Pseudomonas aeruginosa infection when requesting inhaled antibiotic therapy.
    • Prefer agents and dosing regimens consistent with FDA labeling and clinical evidence (e.g., TOBI per FEV1/age labeling; Cayston using Altera system).
    Step Therapy

    Prioritize supportive care for bronchiolitis; document rationale for bronchodilator/steroid use

    For bronchiolitis and viral wheeze, supportive care (oxygenation, hydration, pulse oximetry) is first-line; bronchodilators and corticosteroids are not routinely effective and should not be used routinely without justification.

    • Document supportive care measures and clinical rationale if bronchodilators or steroids are used despite limited evidence.
    • Avoid routine authorization of nebulizer therapy for bronchiolitis unless specific documented indications exist.
    Step Therapy

    Prefer IV magnesium for refractory pediatric asthma; justify nebulized magnesium if requested

    Intravenous magnesium sulfate is supported for pediatric acute asthma refractory to initial therapy; nebulized magnesium has not demonstrated benefit — consider IV route before nebulized magnesium and document rationale if nebulized route is requested.

    • If requesting nebulized magnesium, include evidence-based justification given meta-analysis showing benefit only for IV magnesium.
    • Document prior treatments and reason for selecting nebulized vs IV route.
    Note

    None specified

    No additional provider actions are specified in this section.

    Documentation Required

    Document alternatives tried, compliance, anticipated need, and warranty status

    Physician must document that alternatives (e.g., MDI with or without spacer) were considered and found medically insufficient when required; for replacements include confirmation of compliance, anticipated continued need, and warranty expiration in documentation.

    • Include documentation of alternative therapies tried and clinical rationale for nebulizer necessity.
    • For replacements, include PCP/specialist confirmation of compliance, anticipated continued need, and warranty status.
    Documentation Required

    Include complete plan of care and drug order details on requests

    The plan of care and drug orders must specify the patient’s condition justifying medical necessity and must include the drug name, concentration or mg amount, and volume in each container; an ICD diagnosis code or narrative diagnosis must appear on each order and claim.

    • Ensure the drug order includes exact drug name, concentration or mg amount, and volume.
    • Include a narrative diagnosis and/or ICD code on each order and claim to support medical necessity.
    Note

    Document supervised initial administration and renal/auditory monitoring for inhaled tobramycin

    Document baseline and ongoing monitoring for patients on inhaled tobramycin: initial administration observed by a trained health professional to monitor for bronchospasm; monitor renal function (BUN/creatinine, urinalysis) and obtain audiograms when indicated (concomitant nephrotoxic/ototoxic agents, preexisting dysfunction, or symptoms).

    • Initial dose should be given under supervision and technique education provided to patient/caregiver.
    • Perform BUN/creatinine and urinalysis and audiogram (500–8000 Hz) when clinically indicated; document results and any adverse effects monitoring.
    Documentation Required

    Monitoring and documentation requirements for inhaled tobramycin recipients

    Specifically monitor and document renal function (BUN, creatinine, urinalysis) and audiology (audiogram 500–8000 Hz) for patients on inhaled tobramycin who are receiving concomitant nephrotoxic or ototoxic agents or have preexisting dysfunction; document patient/caregiver education on adverse effects and instructions to stop and notify clinician if symptoms occur.

    • Document baseline labs and audiogram when indicated and repeat monitoring if symptoms or concomitant toxic therapies are present.
    • Record patient/caregiver training on recognition of tinnitus, bronchospasm, urticaria, edema, and instructions to report adverse events.
    Billing Rule

    Provide justification and documentation for replacement requests exceeding usual maximums

    When requesting replacement frequencies that exceed the policy’s usual maximum intervals, include documentation supporting medical necessity (e.g., clinical reasons for increased replacement, proof of warranty expiration, and PCP/specialist confirmation of ongoing need).

    • Reference the policy’s 'Usual Maximum Replacement' intervals and provide clinical justification for exceeding them.
    • Attach evidence of member compliance and device failure/warranty expiration as applicable.
    Documentation Required

    Record MDI ± spacer trials and rationale when required

    Document that an MDI with or without a spacer was considered and found insufficient before requesting a nebulizer when the policy criteria require it; include this in the plan of care and prior authorization materials.

    • Record specifics of MDI trial (drug, dose, spacer use, response) and the reason it was inadequate.
    • Include clinician rationale and objective measures if available (e.g., peak flow, FEV1).
    Note

    Therapeutic preference: follow evidence-based inhaled antibiotic indications and device requirements

    Informational: evidence supports aerosolized tobramycin for maintenance therapy in CF patients chronically infected with Pseudomonas aeruginosa; ensure infection status is documented and dosing/device requirements (e.g., jet nebulizer or Podhaler; Cayston with Altera) are met.

    • Confirm chronic Pseudomonas infection in documentation for inhaled antibiotic requests.
    • Follow product-specific device and dosing instructions (Podhaler for tobramycin powder; Altera for Cayston).
    Step Therapy

    Prefer IV route for magnesium in refractory pediatric asthma; justify nebulized use

    Prefer IV magnesium sulfate for pediatric acute asthma refractory to initial therapy; nebulized magnesium has not shown significant benefit — if nebulized magnesium is requested, include justification referencing prior treatments and rationale.

    • Document prior therapies and clinical reasoning for selecting nebulized rather than IV magnesium.
    • Include relevant trial data or patient-specific contraindications to IV therapy if claiming neb route is necessary.
    Note

    No actions specified in this section

    No specific provider actions are listed in these chunks.

    Denial Risk

    Experimental/investigational uses of nebulizers may be denied

    Use of small volume, large volume, and ultrasonic nebulizers and accessories for indications not specifically listed in the policy is considered experimental/investigational and may result in denial; ensure requested use matches the policy’s listed indications.

    • Confirm the requested indication is one of the policy’s listed medically necessary uses before submission.
    • If the indication is not listed, expect potential denial as experimental/investigational.
    Documentation Required

    Include narrative diagnosis/ICD code and supporting medical record with claims

    Claims for equipment, accessories, and drugs must include a narrative diagnosis and/or ICD code describing the condition necessitating nebulizer therapy; the patient's medical record must support medical necessity for all items ordered.

    • Include an ICD diagnosis and narrative statement of medical necessity on each order and claim.
    • Attach relevant clinical documentation to support the request (e.g., cultures showing Pseudomonas for inhaled antibiotics).
    Denial Risk

    Do not prescribe inhaled antibiotics without documented infection or prophylactic indication

    Do not prescribe inhaled antibiotics (e.g., tobramycin, aztreonam) unless there is a proven or strongly suspected bacterial infection or a prophylactic indication; inhaled antibiotics used without such evidence increase resistance risk and are unlikely to be approved.

    • Document microbiology results or clinical rationale demonstrating proven or strongly suspected infection when requesting inhaled antibiotics.
    • Avoid prophylactic or empiric inhaled antibiotic use without documented indication; include justification if prophylactic use is claimed.
    Denial Risk

    Tobramycin requests without documented infection are at high risk for denial

    Prescribing tobramycin without a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to be approved and may be denied due to risk of resistance; ensure documentation of infection status and adherence to labeled dosing/cycles.

    • Provide microbiology or clinical evidence of Pseudomonas infection when requesting tobramycin therapy.
    • Include documentation of planned 28-day on/28-day off cycles and device type used.

    Clinical Background and Evidence Summary

    Nebulizers are devices that deliver aerosolized medications to the respiratory tract and play a role in treating conditions such as cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease (including chronic bronchitis and emphysema), asthma, and pulmonary arterial hypertension. They are also used to administer specific inhaled anti‑infectives and mucolytics (for example, tobramycin, aztreonam/Cayston, and dornase alfa/Pulmozyme) when indicated and when device‑drug compatibility and labeled administration requirements are met.

    Definitions and Device Terminology

    Small Volume Nebulizer — portable nebulizer and related compressor DME definition and typical uses
    DefinitionPortable small-volume nebulizer and related compressor DME used to administer inhaled medications (antibiotics, bronchodilators, anticholinergics, corticosteroids, mucolytics, pentamidine, colistin, aztreonam) for specified indications.
    Typical usesHome or clinic administration of inhaled antibiotics for CF, bronchodilators for COPD/asthma when MDI/spacer inadequate, mucolytics (e.g., dornase alfa) for CF/primary ciliary dyskinesia, and inhaled pentamidine.
    Device contextNebulizer chamber is accessory attached to an aerosol compressor to create a functioning delivery system for aerosol therapy.
    Ultrasonic Nebulizer — definition and clinical note on necessity
    DefinitionUltrasonic nebulizer (generator) produces smaller particle sizes by ultrasonic vibrations and is distinct from an air-driven compressor.
    Clinical noteConsidered medically necessary only when patient meets standard nebulizer criteria, is compliant with therapy, and standard nebulizer has failed to control disease and prevent hospital/ED utilization.
    LimitationsExperimental/investigational for indications other than specified (e.g., primarily used for tobramycin delivery in specific cases).
    Large Volume Nebulizer — definition and indications (humidity, pentamidine, bronchiectasis)
    DefinitionLarge volume nebulizer and related compressor with water/saline to deliver humidity for patients with thick, tenacious secretions.
    IndicationsAdministration of pentamidine (HIV, pneumocystosis, transplant complications), bronchiectasis, cystic fibrosis, tracheobronchial stent, and tracheostomy.
    Coverage stanceConsidered experimental/investigational for indications other than those listed because effectiveness not established.
    Device terminology — compressor, generator, nebulizer chamber distinctions
    CompressorEquipment that nebulizes liquid by means of air flow (air-driven source).
    GeneratorDevice that nebulizes liquid by ultrasonic vibrations (ultrasonic generator).
    Nebulizer (chamber)Accessory chamber in which nebulization of liquid occurs; attaches to compressor or generator to deliver aerosol therapy.
    FDA-approved nebulized antibiotics — TOBI/TNS and Cayston for CF
    TOBI/TNS (tobramycin)FDA‑approved inhalation solution for maintenance therapy in CF patients with Pseudomonas aeruginosa (300 mg q12h; 28 days on/28 days off).
    Cayston (aztreonam)FDA‑approved aztreonam for inhalation to improve respiratory symptoms in CF patients with P. aeruginosa; 75 mg TID, 28 days on/28 days off, administered with Altera Nebulizer System.
    Brovana (arformoterol) — definition and indication summary
    Agent class and identityBrovana (arformoterol) is a long-acting beta2-agonist (R,R enantiomer of formoterol), inhalation solution delivered via nebulizer.
    IndicationIndicated for twice-daily maintenance treatment of bronchoconstriction in COPD (including chronic bronchitis and emphysema); not for asthma monotherapy or acute deteriorations.
    Clinical notesDemonstrated improvement in FEV1 in pivotal studies; safety in pediatric patients not established.
    Perforomist (formoterol fumarate) — definition and indication summary
    Agent identityPerforomist (formoterol fumarate) is a long-acting beta2-adrenergic agonist inhalation solution.
    IndicationIndicated for long-term, twice-daily maintenance treatment of bronchoconstriction in COPD (chronic bronchitis, emphysema); not for asthma monotherapy or acute exacerbations.
    Safety/REMSLABAs (including formoterol) have FDA REMS requirements and are not indicated for asthma as monotherapy.
    Tyvaso (treprostinil) — inhaled prostacyclin analogue definition and dosing context
    Class and mechanismTyvaso (treprostinil) is an inhaled prostacyclin analogue intended to improve exercise ability in WHO Group 1 pulmonary arterial hypertension.
    Dosing contextAdministered in four equally spaced treatment sessions per day (approximately every 4 hours); titration begins at 3 breaths/session and may increase to 9 breaths (54 mcg) per session if tolerated.
    Device and monitoringDelivered via Optineb-ir/ON-100/7 device; avoid concurrent use with other prostanoids; caution in hepatic/renal impairment.
    Ventavis (iloprost) — inhaled prostacyclin analogue definition and dosing context
    Class and identityVentavis (iloprost) is an inhaled prostacyclin analogue (synthetic PGI2) for WHO Group I PAH.
    Dosing contextInitial inhaled dose 2.5 mcg (increase to 5 mcg if tolerated); administer 6–9 times per day (no more than every 2 hours); max daily dose studied 45 mcg.
    PrecautionsCan induce bronchospasm; use only with designated delivery devices (Prodose AAD or I‑neb AAD); avoid initiation if systolic BP <85 mmHg.
    Cayston (aztreonam inhalation) — definition, indication, dosing context
    Agent identityCayston (aztreonam inhalation solution) is an inhaled monobactam antibiotic for CF patients with Pseudomonas aeruginosa.
    Indication and deviceIndicated for CF patients ≥7 years; must be administered with the Altera Nebulizer System; use bronchodilator prior to dosing as per labeling.
    Dosing and cycle75 mg inhaled three times daily for 28 days on followed by 28 days off; doses taken at least 4 hours apart.
    Tobramycin inhalation — definition and typical dosing/administration context
    Agent classTobramycin inhalation is an aminoglycoside antibiotic indicated for CF patients with Pseudomonas aeruginosa.
    Typical dosing (solution)300 mg inhaled every 12 hours via a jet (breath‑enhanced) nebulizer delivering 1–5 micron particles; administered in 28‑day on/28‑day off cycles.
    Administration notesInitial administration should be supervised to observe for bronchospasm; avoid mixing with other nebulized medications; routine serum levels not required with normal renal function.
    Tobramycin inhalation powder (Tobi Podhaler) — dosing details (4×28 mg capsules every 12 hours)
    Dose per administrationFour 28 mg capsules (112 mg total) inhaled using the Podhaler every 12 hours.
    Dosing cycleAdminister in repeated cycles of 28 days on followed by 28 days off.
    Age/weight112 mg dose is the same regardless of age or weight.
    Tobramycin inhalation solution — 300 mg q12h via jet nebulizer, particle size note
    Solution dosing300 mg by inhalation over ~15 minutes every 12 hours using a jet (breath‑enhanced) nebulizer.
    Particle size noteUse nebulizer that delivers droplet particles between 1 and 5 microns.
    Dosing cycleAdminister in repeated cycles of 28 days on followed by 28 days off.
    PD20 / PC20 — methacholine challenge definitions
    PD20 definitionPD20 is the provocative dose of methacholine producing a 20% fall in FEV1.
    PC20 definitionPC20 is the provocative concentration of methacholine producing a 20% fall in FEV1.
    Reporting preferenceBecause device output differs, reporting airway responsiveness in terms of dose (PD20) rather than concentration (PC20) is preferred.
    Severity of lung disease by FEV1 — normal/mild/moderate/severe thresholds
    Normal> 90% predicted FEV1.
    Mild70%–89% predicted FEV1.
    Moderate40%–69% predicted FEV1.
    Severe< 40% predicted FEV1.

    Policy Revision History

    2023-03-17policy_reviewLatest

    Policy last reviewed on 03/17/2023; effective date remains 12/04/1995 and next review scheduled for 01/11/2024.

    1995-12-04policy_effective

    Policy effective date established as 12/04/1995.

    2024-01-11scheduled_review

    Next review scheduled for 01/11/2024 per policy metadata.